Table 2.
Univariate Incidence of Adverse Events After THA/TKA in Matched Patients With and Without Behcet Syndrome
| THA/TKA No Behcet (N = 1,127) | THA/TKA Behcet (N = 282) | P | |
| Any adverse events | 221 (19.6%) | 94 (33.3%) | <0.0001 |
| Serious adverse events | 104 (9.2%) | 42 (14.9%) | 0.0053 |
| Sepsis | 24 (2.1%) | 16 (5.7%) | 0.0013 |
| Pulmonary embolism | 16 (1.4%) | 11 (3.9%) | 0.0065 |
| Deep vein thrombosis | 36 (3.2%) | 14 (5.0%) | 0.1499 |
| Surgical site infection | 31 (2.8%) | <11 | 0.4777 |
| Minor adverse events | 164 (14.6%) | 79 (28.0%) | <0.0001 |
| Pneumonia | 22 (2.0%) | 23 (8.2%) | <0.0001 |
| Urinary tract infection | 62 (5.5%) | 49 (17.4%) | <0.0001 |
| Wound dehiscence | 22 (2.0%) | <11 | 0.1074 |
| Acute kidney injury | 37 (3.3%) | 16 (5.7%) | 0.0588 |
| Hematoma | 12 (1.1%) | <11 | 0.0026 |
| Transfusion | 40 (3.5%) | <11 | 1.0000 |
THA = total hip arthroplasty, TKA = total knee arthroplasty
aPearlDiver does not provide exact numbers of patients when an outcome is experienced by < 11 patients to preserve patient anonymity.
Bold entries represent statistically significant P values at P < 0.05.